CompletedNCT03247556
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
Researchers compared 400mg SPN-812, 600mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Medication studyAges 12–17United States
Understand this study
What did researchers investigate?
Researchers compared 400mg SPN-812, 600mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Long Beach and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: November 20, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 297
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT03247556
- Official title
Show the full official title
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 400 and 600 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Recruitment & locations
CompletedLong Beach · Colorado Springs · Bradenton
9 more locations
- Lauderhill
- Miami
- Orlando
- Decatur
- Oklahoma City
- Charleston
- Beaumont
- Houston
- Clinton
Questions about this study
What did researchers investigate?
Researchers compared 400mg SPN-812, 600mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, 400mg SPN-812 and 600mg SPN-812.
Who was this study for?
This study was for people with ADHD. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)